(Q51986927)

19 April 2018

title

Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. (English)

1 reference

19 April 2018

author name string

Gui-Hua Zhuang

1

1 reference

19 April 2018

Hong Yan

2

1 reference

19 April 2018

Xue-Liang Wang

3

1 reference

19 April 2018

Lu-Yu Hwang

4

1 reference

19 April 2018

Qian Wu

5

1 reference

19 April 2018

Li-Rong Wang

6

1 reference

19 April 2018

Hai-Yan Gao

7

1 reference

19 April 2018

language of work or name

English

0 references

publication date

15 November 2005

1 reference

19 April 2018

published in

Vaccine

1 reference

19 April 2018

volume

24

1 reference

19 April 2018

issue

12

1 reference

19 April 2018

page(s)

2186-2192

1 reference

19 April 2018

Prevention and control of hepatitis B in China

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Hepatitis B virus biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Hepatitis B vaccine -- do we need boosters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Immunogenicity of hepatitis B vaccines: implications of immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

What level of hepatitis B antibody is protective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Novel hepatitis B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

DNA vaccines: development, standardization and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Immunogenetics of the response to HBsAg vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.004

10.1016/J.VACCINE.2005.11.004

7 January 2021

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018